Incyte moved into a late-stage blood disorder bet by agreeing to buy Star Therapeutics’ Vega subsidiary for $1.25 billion upfront, plus up to $750 million in sales milestones, to secure phase III-stage VGA-039 for von Willebrand disease. Johnson & Johnson simultaneously agreed to acquire Firefly Bio for $1 billion in cash, adding degrader-antibody conjugate (DAC) technology aimed at next-generation targeted protein degradation.